Meneses, Maria JoãoSilvestre, ReginaSousa-Lima, InêsMacedo, Maria Paula2019-09-262019-09-262019-08-191422-0067PURE: 14699127PURE UUID: 3c807e25-9118-4b18-a694-641830856ea5Scopus: 85071756236PubMed: 31430977WOS: 000484411100206http://www.scopus.com/inward/record.url?scp=85071756236&partnerID=8YFLogxKThis work was funded by the "Fundacao para a Ciencia e a Tecnologia"-FCT to Maria J. Meneses (PD/BD/114256/2016); M. Paula Macedo (PTDC/DTP-EPI/0207/2012, PTDC/BIM-MET/2115/2014 and PTDC/BIM-MET/4265/2014); and iNOVA4Health (UID/Multi/04462/2013); by the European Commission Marie Sklodowska-Curie Actions H2020 (grant agreements no. 722619 and no. 734719), and by the Sociedade Portuguesa de Diabetologia GIFT 2018.Metabolic disorders are characterized by an overall state of inflammation and oxidative stress, which highlight the importance of a functional antioxidant system and normal activity of some endogenous enzymes, namely paraoxonase-1 (PON1). PON1 is an antioxidant and anti-inflammatory glycoprotein from the paraoxonases family. It is mainly expressed in the liver and secreted to the bloodstream, where it binds to HDL. Although it was first discovered due to its ability to hydrolyze paraoxon, it is now known to have an antiatherogenic role. Recent studies have shown that PON1 plays a protective role in other diseases that are associated with inflammation and oxidative stress, such as Type 1 and Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. The aim of this review is to elucidate the physiological role of PON1, as well as the impact of altered PON1 levels in metabolic disorders.1090797engdiabetes mellitusglucoseinsulin resistanceNAFLDobesityPON1CatalysisMolecular BiologySpectroscopyComputer Science ApplicationsPhysical and Theoretical ChemistryOrganic ChemistryInorganic ChemistrySDG 3 - Good Health and Well-beingreview10.3390/ijms20164049https://www.scopus.com/pages/publications/85071756236